SenesTech, Inc.
SenesTech, Inc. develops and commercializes fertility-control products for managing rat and mouse populations. Its portfolio includes ContraPest and the Evolve line, which are sold in the United States and through international distributors, with operations centered in Surprise, Arizona.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaLiquid fertility-control product for rat population management.
Fertility-control product for rat control across commercial channels.
Fertility-control product designed for mouse population management.
Sales through overseas distributors and related commercialization support.
Asiakkaat
SenesTech sells to end users that need ongoing rodent population control, including pest management professionals, retailers, and commercial or institutional facilities. The products are also relevant to agricultural and food-related operators where rodents threaten stored goods, infrastructure, and biosecurity. Adoption depends on customers seeking non-lethal, fertility-based alternatives to traditional rodenticides.
Buy Evolve and ContraPest for field use in recurring rodent-control programs.
Purchase rodent fertility-control products through online retail channels for self-directed use.
Use the products to manage rats and mice in buildings, campuses, and operations sites.
Buy to reduce rodent-driven contamination, feed loss, and infrastructure damage.
Distribute products into foreign markets after local regulatory and channel setup.
Strategia
SenesTech is focused on scaling its Evolve product family, expanding e-commerce and retail reach, and strengthening distribution through pest-management professionals and partners. It also seeks additional regulatory approvals and international market access, while improving manufacturing efficiency to support broader commercialization. These priorities are intended to widen adoption of fertility-control rodent management and improve the economics of the business model.
Evolve is the main growth engine and broadens the company's addressable market.
State and foreign approvals determine where products can be sold.
Manufacturing throughput and supplier economics affect scalability and margins.
Partners help reach customers faster and support market education.
Maantiede
Q3/2024SenesTech is headquartered and manufactures in Surprise, Arizona, and its products are sold across the United States. ContraPest is registered in all 50 states plus U.S. territories, while Evolve Rat and Evolve Mouse have more limited state registrations and are also marketed internationally through distributors. Geography matters because regulatory approval, labeling, and distributor relationships determine where each product can be sold.
Riskit
SenesTech depends on market acceptance of a relatively new fertility-control category, so adoption risk is central to the business. Regulatory approvals, channel execution, and supply continuity are also important because the products cannot be sold broadly without registrations and reliable manufacturing inputs. As a small commercial-stage company, it also faces financing, personnel, and product-liability risks typical of early commercialization businesses.
- Commercialization and market acceptance riskVaikutus: KorkeaTodennäköisyys: Korkea
Revenue depends on customers choosing fertility control over traditional rodenticides.
Kohdistuu: ContraPest and Evolve sales
- Financing and liquidity riskVaikutus: KorkeaTodennäköisyys: Korkea
Commercial-stage losses and limited revenue can require external capital.
Kohdistuu: Equity issuance and warrant exercises
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Products require state and foreign registrations before they can be sold in many markets.
Kohdistuu: U.S. states and international jurisdictions
- Supply chain and manufacturing disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company relies on third-party ingredients and a single manufacturing site.
Kohdistuu - Product misuse and liability riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Off-label or improper use could trigger claims, investigations, or reputational damage.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätThe company must estimate future demand to test for excess or obsolete inventory.
Vaikutus: Can create write-downs that reduce gross profit and earnings
Sales are concentrated in a small product set and multiple channels, which can affect timing.
Vaikutus: Can shift quarterly revenue and comparability
A meaningful portion of compensation expense is equity-based for a small issuer.
Vaikutus: Raises operating expenses without immediate cash outflow
Investment purchases and maturities affect liquidity and interest income.
Vaikutus: Changes cash deployment and reported non-operating income
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
enGene Therapeutics Inc.
ENGN · Biological Products, (No Diagnostic Substances)
Seneca Foods Corp
SENEA · Canned, Fruits, Veg, Preserves, Jams & Jellies
Sana Biotechnology, Inc.
SANA · Biological Products, (No Diagnostic Substances)
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Centessa Pharmaceuticals plc
Pharmaceutical Preparations
Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company built around an asset-centric model, where each program is developed with its own…
Senseonics Holdings, Inc.
SENS · Industrial Instruments For Measurement, Display, and Control
Päivitetty: 24.9.2026